Treatment for Chronic Lymphocytic Leukemia (CLL) Blast Crisis

Initial Diagnostic Approach

• The National Comprehensive Cancer Network recommends confirming blast crisis through bone marrow aspirate and biopsy showing ≥20% blasts, and performing immunophenotyping by flow cytometry to characterize the blast population, and conducting cytogenetic analysis with FISH to detect high-risk abnormalities, particularly del(17p)/TP53 mutations, and completing a comprehensive metabolic panel to assess for tumor lysis syndrome risk 2

First-Line Treatment Options

• The National Comprehensive Cancer Network recommends intensive chemotherapy regimens such as R-CHOP or R-HyperCVAD for physically fit patients, and dose-adjusted EPOCH-R as an alternative intensive regimen with activity in transformed lymphomas 1
• For patients with del(17p), the National Comprehensive Cancer Network suggests considering incorporating targeted agents such as BTK inhibitors or venetoclax into the treatment regimen 3

Treatment Considerations Based on Patient Factors

• For younger, fit patients without significant comorbidities, the National Comprehensive Cancer Network recommends intensive chemotherapy followed by evaluation for allogeneic stem cell transplantation, which offers the only potentially curative approach 1

Response Evaluation and Follow-up

• The National Comprehensive Cancer Network recommends assessing treatment response after 2-3 cycles with bone marrow examination and imaging studies, and monitoring closely for complications including tumor lysis syndrome, infections, and cytopenias 3, 4

Management of Refractory Disease

• The National Comprehensive Cancer Network suggests considering clinical trials for patients not responding to initial therapy, and alternative salvage regimens such as OFAR 1

Important Caveats

• The National Comprehensive Cancer Network recommends prophylaxis and close monitoring for tumor lysis syndrome risk, which is high with intensive chemotherapy 2